LENEA FISHER: Open Payments
NPI 1447922018 · RED BLUFF, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,387 in 65 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $312 · 2025 $1,387
Food & beverage: $1,387
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $302 |
| ABBVIE INC. | 11 | $226 |
| PFIZER INC. | 11 | $194 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $152 |
| Novo Nordisk Inc | 6 | $123 |
| Lilly USA, LLC | 5 | $90 |
| AstraZeneca Pharmaceuticals LP | 4 | $75 |
| Lundbeck LLC | 3 | $58 |
| GlaxoSmithKline, LLC. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
Products named: CAPLYTA, VRAYLAR, PREVNAR 20, MOUNJARO, REXULTI, ELIQUIS, Rybelsus, AIRSUPRA.
Industry payments across CA — which companies pay providers there.
